| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
37 |
| Employees |
10 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-434 |
| Cash Flow (TTM) (Millions $) |
-64 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for mental health disorders. The company is headquartered in Boston, Massachusetts and was founded in 2009 by Dr. Andrew Miller and Dr. Mark Gurney.
Karunaes mission is to help patients with debilitating psychiatric conditions by discovering and developing medications that target the underlying biological mechanisms of the disease. The company believes that by targeting these mechanisms, they can provide more effective treatments that address the root causes of mental health disorders.
Karuna Therapeuticse lead product candidate is called KarXT, which is a combination of xanomeline and trospium chloride. Xanomeline is a muscarinic acetylcholine receptor agonist that has been shown to improve symptoms of schizophrenia and Alzheimeres disease, while trospium chloride is an approved medication used to treat overactive bladder. The combination of these two drugs has the potential to alleviate schizophrenia symptoms while minimizing side effects such as excessive salivation and gastrointestinal troubles.
Karuna is also developing other therapies for mental health conditions such as depression and anxiety disorders. The companyes preclinical pipeline includes novel compounds that target the glutamatergic system, which is believed to play a role in depression and anxiety.
Karuna Therapeutics has raised over $200 million in funding to date, including a successful initial public offering in 2019. The company has also partnered with various academic and industry partners to advance its research and development efforts.
The management team at Karuna has deep expertise in both drug development and psychiatry/psychology, with several members holding doctorates or other advanced degrees in these areas. This expertise has enabled the company to rapidly advance its drug development programs and secure funding from top-tier investors.
Overall, Karuna Therapeutics is a promising company that is well-positioned to make significant contributions to the treatment of mental health disorders in the future.
Company Address: 99 High Street Boston 2110 MA
Company Phone Number: 449-2244 Stock Exchange / Ticker: NASDAQ KRTX
|
%
0.25%